Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo ...

Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

Semaglutide and Atrial Fibrillation A subanalysis of data from the STEP-HFpEF and STEP-HFpEF DM trials 5 showed that patients with aFib—45% of the STEP-HFpEF program population—have greatly ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular ...

1 The STEP-HFpEF Program enrolled participants with obesity-related HFpEF; in SELECT (participants with atherosclerotic cardiovascular (CV) disease and overweight/obesity) and FLOW (participants ...

STEP-HFpEF, and STEP-HFpEF DM trials. According to the analysis, semaglutide led to a 31% reduced risk of combined cardiovascular (CV) death or worsening heart failure (HF) events, based on an ...

After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. Novo’s semaglutide cut the ...